Will canagliflozin (SGLT2 inhibitor) plus low-dose rapamycin show synergy in old marmosets — HSC rejuvenation without high-dose immunosuppression?
Chance it happens
33%Belief the predicted event happens at all — every “yes / by-a-date” outcome added together. “Other” is tracked as its own third slice.
Outcomes
Resolution criteria
A peer-reviewed study in old marmosets reports synergistic hematopoietic stem-cell rejuvenation from canagliflozin plus low-dose rapamycin without the immunosuppression characteristic of high-dose rapamycin. Resolution horizon: 2030-12-31. Source: peer-reviewed publication.
Evidence & context
Trials, publications and reports our research found on this prognosis. Each links to the original source.
This is a news/forum post summarizing a 2021 MIT study in mice reporting that rapamycin helped preserve blood stem-cell function by preventing cellular enlargement. It bears indirectly on the prediction because it supports rapamycin as an HSC-rejuvenation mechanism, but it provides no direct evidence about canagliflozin, combination synergy, old marmosets, or low-dose immunosuppression.
This appears to be a peer-reviewed PMC publication discussing potential synergy between mTOR inhibition (e.g., rapamycin) and SGLT2 inhibitors in aging-related biology. It bears on the prediction indirectly by supporting mechanistic plausibility, but it does not by itself establish the required old-marmoset HSC rejuvenation result without high-dose rapamycin-like immunosuppression.